Global Lacosamide Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Lacosamide Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Lacosamide Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Tablets
1.2.3 Injection
1.2.4 Oral Solution
1.3 Market Segmentation by Application
1.3.1 Global Lacosamide Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Lacosamide Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Lacosamide Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Lacosamide Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Lacosamide Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Lacosamide Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Lacosamide Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Tablets Market Size by Manufacturers
3.5.2 Injection Market Size by Manufacturers
3.5.3 Oral Solution Market Size by Manufacturers
3.6 Global Lacosamide Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Lacosamide Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Lacosamide Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Lacosamide Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Lacosamide Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Lacosamide Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Lacosamide Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Lacosamide Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Lacosamide Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Lacosamide Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Lacosamide Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Lacosamide Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Lacosamide Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Lacosamide Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Lacosamide Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Lacosamide Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Lacosamide Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Lacosamide Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Lacosamide Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Lacosamide Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 UCB Pharma
11.1.1 UCB Pharma Corporation Information
11.1.2 UCB Pharma Business Overview
11.1.3 UCB Pharma Lacosamide Drugs Product Models, Descriptions and Specifications
11.1.4 UCB Pharma Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 UCB Pharma Lacosamide Drugs Sales by Product in 2024
11.1.6 UCB Pharma Lacosamide Drugs Sales by Application in 2024
11.1.7 UCB Pharma Lacosamide Drugs Sales by Geographic Area in 2024
11.1.8 UCB Pharma Lacosamide Drugs SWOT Analysis
11.1.9 UCB Pharma Recent Developments
11.2 Glenmark Pharmaceuticals
11.2.1 Glenmark Pharmaceuticals Corporation Information
11.2.2 Glenmark Pharmaceuticals Business Overview
11.2.3 Glenmark Pharmaceuticals Lacosamide Drugs Product Models, Descriptions and Specifications
11.2.4 Glenmark Pharmaceuticals Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Glenmark Pharmaceuticals Lacosamide Drugs Sales by Product in 2024
11.2.6 Glenmark Pharmaceuticals Lacosamide Drugs Sales by Application in 2024
11.2.7 Glenmark Pharmaceuticals Lacosamide Drugs Sales by Geographic Area in 2024
11.2.8 Glenmark Pharmaceuticals Lacosamide Drugs SWOT Analysis
11.2.9 Glenmark Pharmaceuticals Recent Developments
11.3 Camber Pharma
11.3.1 Camber Pharma Corporation Information
11.3.2 Camber Pharma Business Overview
11.3.3 Camber Pharma Lacosamide Drugs Product Models, Descriptions and Specifications
11.3.4 Camber Pharma Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Camber Pharma Lacosamide Drugs Sales by Product in 2024
11.3.6 Camber Pharma Lacosamide Drugs Sales by Application in 2024
11.3.7 Camber Pharma Lacosamide Drugs Sales by Geographic Area in 2024
11.3.8 Camber Pharma Lacosamide Drugs SWOT Analysis
11.3.9 Camber Pharma Recent Developments
11.4 Actavis
11.4.1 Actavis Corporation Information
11.4.2 Actavis Business Overview
11.4.3 Actavis Lacosamide Drugs Product Models, Descriptions and Specifications
11.4.4 Actavis Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Actavis Lacosamide Drugs Sales by Product in 2024
11.4.6 Actavis Lacosamide Drugs Sales by Application in 2024
11.4.7 Actavis Lacosamide Drugs Sales by Geographic Area in 2024
11.4.8 Actavis Lacosamide Drugs SWOT Analysis
11.4.9 Actavis Recent Developments
11.5 Sandoz
11.5.1 Sandoz Corporation Information
11.5.2 Sandoz Business Overview
11.5.3 Sandoz Lacosamide Drugs Product Models, Descriptions and Specifications
11.5.4 Sandoz Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sandoz Lacosamide Drugs Sales by Product in 2024
11.5.6 Sandoz Lacosamide Drugs Sales by Application in 2024
11.5.7 Sandoz Lacosamide Drugs Sales by Geographic Area in 2024
11.5.8 Sandoz Lacosamide Drugs SWOT Analysis
11.5.9 Sandoz Recent Developments
11.6 Teva
11.6.1 Teva Corporation Information
11.6.2 Teva Business Overview
11.6.3 Teva Lacosamide Drugs Product Models, Descriptions and Specifications
11.6.4 Teva Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Teva Recent Developments
11.7 Apotex
11.7.1 Apotex Corporation Information
11.7.2 Apotex Business Overview
11.7.3 Apotex Lacosamide Drugs Product Models, Descriptions and Specifications
11.7.4 Apotex Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Apotex Recent Developments
11.8 Mylan
11.8.1 Mylan Corporation Information
11.8.2 Mylan Business Overview
11.8.3 Mylan Lacosamide Drugs Product Models, Descriptions and Specifications
11.8.4 Mylan Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Mylan Recent Developments
11.9 Sun Pharma
11.9.1 Sun Pharma Corporation Information
11.9.2 Sun Pharma Business Overview
11.9.3 Sun Pharma Lacosamide Drugs Product Models, Descriptions and Specifications
11.9.4 Sun Pharma Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Sun Pharma Recent Developments
11.10 Aucta Pharma
11.10.1 Aucta Pharma Corporation Information
11.10.2 Aucta Pharma Business Overview
11.10.3 Aucta Pharma Lacosamide Drugs Product Models, Descriptions and Specifications
11.10.4 Aucta Pharma Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Aucta Pharma Recent Developments
11.11 Hefei Yifan Biopharmaceuticals
11.11.1 Hefei Yifan Biopharmaceuticals Corporation Information
11.11.2 Hefei Yifan Biopharmaceuticals Business Overview
11.11.3 Hefei Yifan Biopharmaceuticals Lacosamide Drugs Product Models, Descriptions and Specifications
11.11.4 Hefei Yifan Biopharmaceuticals Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Hefei Yifan Biopharmaceuticals Recent Developments
11.12 Jiangsu Haian Pharmaceutical
11.12.1 Jiangsu Haian Pharmaceutical Corporation Information
11.12.2 Jiangsu Haian Pharmaceutical Business Overview
11.12.3 Jiangsu Haian Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.12.4 Jiangsu Haian Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Jiangsu Haian Pharmaceutical Recent Developments
11.13 CSPC Ouyi Pharmaceutical
11.13.1 CSPC Ouyi Pharmaceutical Corporation Information
11.13.2 CSPC Ouyi Pharmaceutical Business Overview
11.13.3 CSPC Ouyi Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.13.4 CSPC Ouyi Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 CSPC Ouyi Pharmaceutical Recent Developments
11.14 Shijiazhuang No.4 Pharmaceutical
11.14.1 Shijiazhuang No.4 Pharmaceutical Corporation Information
11.14.2 Shijiazhuang No.4 Pharmaceutical Business Overview
11.14.3 Shijiazhuang No.4 Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.14.4 Shijiazhuang No.4 Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Shijiazhuang No.4 Pharmaceutical Recent Developments
11.15 Shandong Loncom Pharmaceutical
11.15.1 Shandong Loncom Pharmaceutical Corporation Information
11.15.2 Shandong Loncom Pharmaceutical Business Overview
11.15.3 Shandong Loncom Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.15.4 Shandong Loncom Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Shandong Loncom Pharmaceutical Recent Developments
11.16 Jianmin Group
11.16.1 Jianmin Group Corporation Information
11.16.2 Jianmin Group Business Overview
11.16.3 Jianmin Group Lacosamide Drugs Product Models, Descriptions and Specifications
11.16.4 Jianmin Group Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Jianmin Group Recent Developments
11.17 Jiangxi Qingfeng Pharmaceutical
11.17.1 Jiangxi Qingfeng Pharmaceutical Corporation Information
11.17.2 Jiangxi Qingfeng Pharmaceutical Business Overview
11.17.3 Jiangxi Qingfeng Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.17.4 Jiangxi Qingfeng Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Jiangxi Qingfeng Pharmaceutical Recent Developments
11.18 Beijing Sihuan Pharmaceutical
11.18.1 Beijing Sihuan Pharmaceutical Corporation Information
11.18.2 Beijing Sihuan Pharmaceutical Business Overview
11.18.3 Beijing Sihuan Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.18.4 Beijing Sihuan Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Beijing Sihuan Pharmaceutical Recent Developments
11.19 Zhejiang Huahai Pharmaceutical
11.19.1 Zhejiang Huahai Pharmaceutical Corporation Information
11.19.2 Zhejiang Huahai Pharmaceutical Business Overview
11.19.3 Zhejiang Huahai Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.19.4 Zhejiang Huahai Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.19.5 Zhejiang Huahai Pharmaceutical Recent Developments
11.20 Buchang Pharmaceutical
11.20.1 Buchang Pharmaceutical Corporation Information
11.20.2 Buchang Pharmaceutical Business Overview
11.20.3 Buchang Pharmaceutical Lacosamide Drugs Product Models, Descriptions and Specifications
11.20.4 Buchang Pharmaceutical Lacosamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.20.5 Buchang Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Lacosamide Drugs Industry Chain
12.2 Lacosamide Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Lacosamide Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Lacosamide Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Lacosamide Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Lacosamide Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Lacosamide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Lacosamide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Lacosamide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Lacosamide Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Lacosamide Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Lacosamide Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Lacosamide Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Lacosamide Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Lacosamide Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Lacosamide Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Lacosamide Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Lacosamide Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Lacosamide Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lacosamide Drugs as of 2024)
Table 16. Global Lacosamide Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Lacosamide Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Lacosamide Drugs Manufacturing Base and Headquarters
Table 19. Global Lacosamide Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Lacosamide Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Lacosamide Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Lacosamide Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Lacosamide Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Lacosamide Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Lacosamide Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Lacosamide Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Lacosamide Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Lacosamide Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Lacosamide Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Lacosamide Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Lacosamide Drugs Growth Accelerators and Market Barriers
Table 37. North America Lacosamide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Lacosamide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Lacosamide Drugs Growth Accelerators and Market Barriers
Table 40. Europe Lacosamide Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Lacosamide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Lacosamide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Lacosamide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Lacosamide Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Lacosamide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Lacosamide Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Lacosamide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Lacosamide Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Lacosamide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. UCB Pharma Corporation Information
Table 51. UCB Pharma Description and Major Businesses
Table 52. UCB Pharma Product Models, Descriptions and Specifications
Table 53. UCB Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. UCB Pharma Sales Value Proportion by Product in 2024
Table 55. UCB Pharma Sales Value Proportion by Application in 2024
Table 56. UCB Pharma Sales Value Proportion by Geographic Area in 2024
Table 57. UCB Pharma Lacosamide Drugs SWOT Analysis
Table 58. UCB Pharma Recent Developments
Table 59. Glenmark Pharmaceuticals Corporation Information
Table 60. Glenmark Pharmaceuticals Description and Major Businesses
Table 61. Glenmark Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Glenmark Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Glenmark Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Glenmark Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Glenmark Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Glenmark Pharmaceuticals Lacosamide Drugs SWOT Analysis
Table 67. Glenmark Pharmaceuticals Recent Developments
Table 68. Camber Pharma Corporation Information
Table 69. Camber Pharma Description and Major Businesses
Table 70. Camber Pharma Product Models, Descriptions and Specifications
Table 71. Camber Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Camber Pharma Sales Value Proportion by Product in 2024
Table 73. Camber Pharma Sales Value Proportion by Application in 2024
Table 74. Camber Pharma Sales Value Proportion by Geographic Area in 2024
Table 75. Camber Pharma Lacosamide Drugs SWOT Analysis
Table 76. Camber Pharma Recent Developments
Table 77. Actavis Corporation Information
Table 78. Actavis Description and Major Businesses
Table 79. Actavis Product Models, Descriptions and Specifications
Table 80. Actavis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Actavis Sales Value Proportion by Product in 2024
Table 82. Actavis Sales Value Proportion by Application in 2024
Table 83. Actavis Sales Value Proportion by Geographic Area in 2024
Table 84. Actavis Lacosamide Drugs SWOT Analysis
Table 85. Actavis Recent Developments
Table 86. Sandoz Corporation Information
Table 87. Sandoz Description and Major Businesses
Table 88. Sandoz Product Models, Descriptions and Specifications
Table 89. Sandoz Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sandoz Sales Value Proportion by Product in 2024
Table 91. Sandoz Sales Value Proportion by Application in 2024
Table 92. Sandoz Sales Value Proportion by Geographic Area in 2024
Table 93. Sandoz Lacosamide Drugs SWOT Analysis
Table 94. Sandoz Recent Developments
Table 95. Teva Corporation Information
Table 96. Teva Description and Major Businesses
Table 97. Teva Product Models, Descriptions and Specifications
Table 98. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Teva Recent Developments
Table 100. Apotex Corporation Information
Table 101. Apotex Description and Major Businesses
Table 102. Apotex Product Models, Descriptions and Specifications
Table 103. Apotex Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Apotex Recent Developments
Table 105. Mylan Corporation Information
Table 106. Mylan Description and Major Businesses
Table 107. Mylan Product Models, Descriptions and Specifications
Table 108. Mylan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Mylan Recent Developments
Table 110. Sun Pharma Corporation Information
Table 111. Sun Pharma Description and Major Businesses
Table 112. Sun Pharma Product Models, Descriptions and Specifications
Table 113. Sun Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Sun Pharma Recent Developments
Table 115. Aucta Pharma Corporation Information
Table 116. Aucta Pharma Description and Major Businesses
Table 117. Aucta Pharma Product Models, Descriptions and Specifications
Table 118. Aucta Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Aucta Pharma Recent Developments
Table 120. Hefei Yifan Biopharmaceuticals Corporation Information
Table 121. Hefei Yifan Biopharmaceuticals Description and Major Businesses
Table 122. Hefei Yifan Biopharmaceuticals Product Models, Descriptions and Specifications
Table 123. Hefei Yifan Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Hefei Yifan Biopharmaceuticals Recent Developments
Table 125. Jiangsu Haian Pharmaceutical Corporation Information
Table 126. Jiangsu Haian Pharmaceutical Description and Major Businesses
Table 127. Jiangsu Haian Pharmaceutical Product Models, Descriptions and Specifications
Table 128. Jiangsu Haian Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Jiangsu Haian Pharmaceutical Recent Developments
Table 130. CSPC Ouyi Pharmaceutical Corporation Information
Table 131. CSPC Ouyi Pharmaceutical Description and Major Businesses
Table 132. CSPC Ouyi Pharmaceutical Product Models, Descriptions and Specifications
Table 133. CSPC Ouyi Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. CSPC Ouyi Pharmaceutical Recent Developments
Table 135. Shijiazhuang No.4 Pharmaceutical Corporation Information
Table 136. Shijiazhuang No.4 Pharmaceutical Description and Major Businesses
Table 137. Shijiazhuang No.4 Pharmaceutical Product Models, Descriptions and Specifications
Table 138. Shijiazhuang No.4 Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Shijiazhuang No.4 Pharmaceutical Recent Developments
Table 140. Shandong Loncom Pharmaceutical Corporation Information
Table 141. Shandong Loncom Pharmaceutical Description and Major Businesses
Table 142. Shandong Loncom Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Shandong Loncom Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Shandong Loncom Pharmaceutical Recent Developments
Table 145. Jianmin Group Corporation Information
Table 146. Jianmin Group Description and Major Businesses
Table 147. Jianmin Group Product Models, Descriptions and Specifications
Table 148. Jianmin Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Jianmin Group Recent Developments
Table 150. Jiangxi Qingfeng Pharmaceutical Corporation Information
Table 151. Jiangxi Qingfeng Pharmaceutical Description and Major Businesses
Table 152. Jiangxi Qingfeng Pharmaceutical Product Models, Descriptions and Specifications
Table 153. Jiangxi Qingfeng Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Jiangxi Qingfeng Pharmaceutical Recent Developments
Table 155. Beijing Sihuan Pharmaceutical Corporation Information
Table 156. Beijing Sihuan Pharmaceutical Description and Major Businesses
Table 157. Beijing Sihuan Pharmaceutical Product Models, Descriptions and Specifications
Table 158. Beijing Sihuan Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Beijing Sihuan Pharmaceutical Recent Developments
Table 160. Zhejiang Huahai Pharmaceutical Corporation Information
Table 161. Zhejiang Huahai Pharmaceutical Description and Major Businesses
Table 162. Zhejiang Huahai Pharmaceutical Product Models, Descriptions and Specifications
Table 163. Zhejiang Huahai Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 164. Zhejiang Huahai Pharmaceutical Recent Developments
Table 165. Buchang Pharmaceutical Corporation Information
Table 166. Buchang Pharmaceutical Description and Major Businesses
Table 167. Buchang Pharmaceutical Product Models, Descriptions and Specifications
Table 168. Buchang Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 169. Buchang Pharmaceutical Recent Developments
Table 170. Key Raw Materials Distribution
Table 171. Raw Materials Key Suppliers
Table 172. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 173. Milestones in Production Technology Evolution
Table 174. Distributors List
Table 175. Market Trends and Market Evolution
Table 176. Market Drivers and Opportunities
Table 177. Market Challenges, Risks, and Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources


List of Figures
Figure 1. Lacosamide Drugs Product Picture
Figure 2. Global Lacosamide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Tablets Product Picture
Figure 4. Injection Product Picture
Figure 5. Oral Solution Product Picture
Figure 6. Global Lacosamide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital and Clinic
Figure 8. Retail Pharmacies
Figure 9. Other
Figure 10. Lacosamide Drugs Report Years Considered
Figure 11. Global Lacosamide Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 13. Global Lacosamide Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Lacosamide Drugs Revenue Market Share by Region (2020-2031)
Figure 15. Global Lacosamide Drugs Sales (2020-2031) & (K Units)
Figure 16. Global Lacosamide Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Lacosamide Drugs Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Lacosamide Drugs Sales Volume Market Share in 2024
Figure 19. Global Lacosamide Drugs Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Tablets Revenue Market Share by Manufacturer in 2024
Figure 22. Injection Revenue Market Share by Manufacturer in 2024
Figure 23. Oral Solution Revenue Market Share by Manufacturer in 2024
Figure 24. Global Lacosamide Drugs Sales Market Share by Type (2020-2031)
Figure 25. Global Lacosamide Drugs Revenue Market Share by Type (2020-2031)
Figure 26. Global Lacosamide Drugs Sales Market Share by Application (2020-2031)
Figure 27. Global Lacosamide Drugs Revenue Market Share by Application (2020-2031)
Figure 28. North America Lacosamide Drugs Sales YoY (2020-2031) & (K Units)
Figure 29. North America Lacosamide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Lacosamide Drugs Sales Revenue (US$ Million) in 2024
Figure 31. North America Lacosamide Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Lacosamide Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Lacosamide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Lacosamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Lacosamide Drugs Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Lacosamide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Lacosamide Drugs Sales Revenue (US$ Million) in 2024
Figure 41. Europe Lacosamide Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Lacosamide Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Lacosamide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Lacosamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. France Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Lacosamide Drugs Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Lacosamide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Lacosamide Drugs Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Lacosamide Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Lacosamide Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Lacosamide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Lacosamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. India Lacosamide Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Lacosamide Drugs Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Lacosamide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Lacosamide Drugs Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Lacosamide Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Lacosamide Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Lacosamide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Lacosamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Lacosamide Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Lacosamide Drugs Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Lacosamide Drugs Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Lacosamide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Lacosamide Drugs Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Lacosamide Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Lacosamide Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Lacosamide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Lacosamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Lacosamide Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Lacosamide Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Lacosamide Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Lacosamide Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. Lacosamide Drugs Industry Chain Mapping
Figure 83. Regional Lacosamide Drugs Manufacturing Base Distribution (%)
Figure 84. Global Lacosamide Drugs Production Market Share by Region (2020-2031)
Figure 85. Lacosamide Drugs Production Process
Figure 86. Regional Lacosamide Drugs Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit